191 related articles for article (PubMed ID: 22409817)
21. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.
Yuan E; Li CM; Yamashiro DJ; Kandel J; Thaker H; Murty VV; Tycko B
Mol Cancer Res; 2005 Sep; 3(9):493-502. PubMed ID: 16179496
[TBL] [Abstract][Full Text] [Related]
22. Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene.
Huff V
Nat Rev Cancer; 2011 Feb; 11(2):111-21. PubMed ID: 21248786
[TBL] [Abstract][Full Text] [Related]
23. Significant reduction of WT1 gene expression, possibly due to epigenetic alteration in Wilms' tumor.
Satoh Y; Nakagawachi T; Nakadate H; Kaneko Y; Masaki Z; Mukai T; Soejima H
J Biochem; 2003 Mar; 133(3):303-8. PubMed ID: 12761165
[TBL] [Abstract][Full Text] [Related]
24. Characterization of 17.94, a novel anaplastic Wilms' tumor cell line.
Brown KW; Charles A; Dallosso A; White G; Charlet J; Standen GR; Malik K
Cancer Genet; 2012 Jun; 205(6):319-26. PubMed ID: 22749038
[TBL] [Abstract][Full Text] [Related]
25. An X chromosome gene, WTX, is commonly inactivated in Wilms tumor.
Rivera MN; Kim WJ; Wells J; Driscoll DR; Brannigan BW; Han M; Kim JC; Feinberg AP; Gerald WL; Vargas SO; Chin L; Iafrate AJ; Bell DW; Haber DA
Science; 2007 Feb; 315(5812):642-5. PubMed ID: 17204608
[TBL] [Abstract][Full Text] [Related]
26. Genetic and epigenetic alterations on the short arm of chromosome 11 are involved in a majority of sporadic Wilms' tumours.
Satoh Y; Nakadate H; Nakagawachi T; Higashimoto K; Joh K; Masaki Z; Uozumi J; Kaneko Y; Mukai T; Soejima H
Br J Cancer; 2006 Aug; 95(4):541-7. PubMed ID: 16909133
[TBL] [Abstract][Full Text] [Related]
27. Nephron Progenitor But Not Stromal Progenitor Cells Give Rise to Wilms Tumors in Mouse Models with β-Catenin Activation or Wt1 Ablation and Igf2 Upregulation.
Huang L; Mokkapati S; Hu Q; Ruteshouser EC; Hicks MJ; Huff V
Neoplasia; 2016 Feb; 18(2):71-81. PubMed ID: 26936393
[TBL] [Abstract][Full Text] [Related]
28. Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology.
Royer-Pokora B; Weirich A; Schumacher V; Uschkereit C; Beier M; Leuschner I; Graf N; Autschbach F; Schneider D; von Harrach M
Cancer; 2008 Sep; 113(5):1080-9. PubMed ID: 18618575
[TBL] [Abstract][Full Text] [Related]
29. Frequency and timing of loss of imprinting at 11p13 and 11p15 in Wilms' tumor development.
Brown KW; Power F; Moore B; Charles AK; Malik KT
Mol Cancer Res; 2008 Jul; 6(7):1114-23. PubMed ID: 18644976
[TBL] [Abstract][Full Text] [Related]
30. CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.
Li CM; Kim CE; Margolin AA; Guo M; Zhu J; Mason JM; Hensle TW; Murty VV; Grundy PE; Fearon ER; D'Agati V; Licht JD; Tycko B
Am J Pathol; 2004 Dec; 165(6):1943-53. PubMed ID: 15579438
[TBL] [Abstract][Full Text] [Related]
31. Association of chromosome arm 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor.
Mummert SK; Lobanenkov VA; Feinberg AP
Genes Chromosomes Cancer; 2005 Jun; 43(2):155-61. PubMed ID: 15761865
[TBL] [Abstract][Full Text] [Related]
32. Wilms tumor arising in a child with X-linked nephrogenic diabetes insipidus.
El-Kares R; Hueber PA; Blumenkrantz M; Iglesias D; Ma K; Jabado N; Bichet DG; Goodyer P
Pediatr Nephrol; 2009 Jul; 24(7):1313-9. PubMed ID: 19294427
[TBL] [Abstract][Full Text] [Related]
33. The development of Wilms tumor: from WT1 and microRNA to animal models.
Tian F; Yourek G; Shi X; Yang Y
Biochim Biophys Acta; 2014 Aug; 1846(1):180-7. PubMed ID: 25018051
[TBL] [Abstract][Full Text] [Related]
34. Altered expression of imprinted genes in Wilms tumors.
Hubertus J; Lacher M; Rottenkolber M; Müller-Höcker J; Berger M; Stehr M; von Schweinitz D; Kappler R
Oncol Rep; 2011 Mar; 25(3):817-23. PubMed ID: 21174059
[TBL] [Abstract][Full Text] [Related]
35. Wt1 ablation and Igf2 upregulation in mice result in Wilms tumors with elevated ERK1/2 phosphorylation.
Hu Q; Gao F; Tian W; Ruteshouser EC; Wang Y; Lazar A; Stewart J; Strong LC; Behringer RR; Huff V
J Clin Invest; 2011 Jan; 121(1):174-83. PubMed ID: 21123950
[TBL] [Abstract][Full Text] [Related]
36. Wilms tumor: an update.
Al-Hussain T; Ali A; Akhtar M
Adv Anat Pathol; 2014 May; 21(3):166-73. PubMed ID: 24713986
[TBL] [Abstract][Full Text] [Related]
37. Frequent association of beta-catenin and WT1 mutations in Wilms tumors.
Maiti S; Alam R; Amos CI; Huff V
Cancer Res; 2000 Nov; 60(22):6288-92. PubMed ID: 11103785
[TBL] [Abstract][Full Text] [Related]
38. Is predisposition for nephroblastoma linked to polymorphisms of the WTX gene?
Guertl B; Leuschner I; Guelly C; Ebner B; Kronberger C; Hoefler G
Pathol Oncol Res; 2010 Jun; 16(2):189-91. PubMed ID: 19757195
[TBL] [Abstract][Full Text] [Related]
39. Increased expression of the insulin-like growth factor-II gene in Wilms' tumor is not dependent on loss of genomic imprinting or loss of heterozygosity.
Wang WH; Duan JX; Vu TH; Hoffman AR
J Biol Chem; 1996 Nov; 271(44):27863-70. PubMed ID: 8910385
[TBL] [Abstract][Full Text] [Related]
40. Imprinting, expression, and localisation of DLK1 in Wilms tumours.
Fukuzawa R; Heathcott RW; Morison IM; Reeve AE
J Clin Pathol; 2005 Feb; 58(2):145-50. PubMed ID: 15677533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
